Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs.

It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.

In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/" for systemic delivery.

The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.